Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M81.3Revenue $M15.2Net Margin (%)-108.4Z-Score0.4
Enterprise Value $M31.9EPS $-0.2Operating Margin %-109.3F-Score6
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-108.4Higher ROA y-yY
Price/Book1.610-y EBITDA Growth Rate %-16.6Quick Ratio11.7Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %-22.2Current Ratio11.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-26.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M90.4ROI % (ttm)-39.5Gross Margin Increase y-yY

Gurus Latest Trades with VICL

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VICLJohn Rogers 2013-12-31 Add0.03%$1.015 - $1.49
($1.2)
$ 0.90-33%Add 39.31%7,062,104
VICLJohn Rogers 2013-06-30 Add0.13%$2.93 - $4.22
($3.52)
$ 0.90-291%Add 93.26%5,134,817
VICLJohn Rogers 2013-03-31 Add0.08%$2.91 - $4.26
($3.54)
$ 0.90-293%Add 71.60%2,656,967
VICLJohn Burbank 2012-12-31 Sold Out -0.05%$2.74 - $4.32
($3.31)
$ 0.90-268%Sold Out0
VICLJohn Rogers 2012-12-31 Add0.03%$2.74 - $4.32
($3.31)
$ 0.90-268%Add 49.50%1,548,357
VICLJohn Burbank 2012-09-30 Buy 0.05%$3.3 - $4.58
($3.69)
$ 0.90-310%New holding250,000
VICLJohn Rogers 2012-03-31 Add0.01%$3.02 - $4.28
($3.23)
$ 0.90-259%Add 26.34%877,193
VICLJohn Rogers 2011-06-30 Reduce-0.01%$2.88 - $4.81
($3.75)
$ 0.90-317%Reduce -30.97%577,773
VICLJohn Rogers 2010-09-30 Add0.03%$2.21 - $3.86
($3.2)
$ 0.90-256%Add 548.18%795,728
VICLJohn Rogers 2009-06-30 Buy 0.01%$1.95 - $2.76
($2.28)
$ 0.90-153%New holding137,198
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VICL is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


VICL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramos Anthony AlanVP, Chief Accounting Officer 2015-01-21Sell428$1.09-21.1view
SAMANT VIJAY BPresident & CEO 2015-01-13Sell4,737$1.12-23.21view
BILINSKY IGORSr VP, Corporate Development 2015-01-12Sell1,335$1.16-25.86view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2015-01-12Sell1,912$1.16-25.86view
Ramos Anthony AlanVP, Chief Accounting Officer 2014-10-21Sell428$1.18-27.12view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2014-10-13Sell1,912$1.08-20.37view
SAMANT VIJAY BPresident & CEO 2014-10-13Sell4,738$1.13-23.89view
BILINSKY IGORSr VP, Corporate Development 2014-10-13Sell1,335$1.08-20.37view
BILINSKY IGORSenior VP, Corporate Dev't 2014-08-26Sell12,500$1.25-31.2view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2014-08-26Sell12,500$1.25-31.2view

Press Releases about VICL :

    Quarterly/Annual Reports about VICL:

    News about VICL:

    Articles On GuruFocus.com
    Red Hat (RHT) and Five Below (FIVE) Strong Performance Metrics; Vical (VICL) Targets Multi-billion S Mar 26 2015 
    John Rogers Comments on Vical Feb 26 2014 
    Kids Decide on Dolls or Devices - JAKK, Others 70% Off Sep 17 2013 
    comment on VICL Mar 02 2013 
    Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
    Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
    Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
    Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 21 2011 
    Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Vical Inc. Reports Operating Results (10-Q) May 07 2010 


    More From Other Websites
    Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
    VICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Mar 25 2015
    Conference-Vical ASP2397 Antifungal In-License for Vical, Inc. Mar 25 2015
    Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Mar 25 2015
    Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Mar 25 2015
    Vical to Present at the 27th Annual ROTH Conference Mar 09 2015
    Vical to Present at the 27th Annual ROTH Conference Mar 05 2015
    Vical Reports Fourth Quarter 2014 Financial Results and Progress in Key Development Programs Mar 03 2015
    VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 02 2015
    Vical reports 4Q loss Feb 26 2015
    Vical reports 4Q loss Feb 26 2015
    Vical Reports Fourth Quarter 2014 Financial Results and Progress in Key Development Programs Feb 26 2015
    Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2014 Financial Results Feb 20 2015
    Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2014 Financial Results Feb 19 2015
    Vical to Present at the Leerink Global Healthcare Conference Feb 09 2015
    Vical to Present at the Leerink Global Healthcare Conference Feb 09 2015
    Cramer: Show some forbearance on this stock Feb 09 2015
    Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Jan 15 2015
    Vical and AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease Jan 14 2015
    Vical and AnGes Announce Collaboration to Develop Therapy for Ebola Virus Disease Jan 14 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK